Astria Therapeutics — Investor Presentation (January 2025)
38 slides from Astria Therapeutics's investor presentation, Jan 13, 2025
Slide 1: Corporate Presentation January 2025
Corporate Presentation January 2025 1
Slide 2: Forward-looking statements
FLS This presentation contains forward - looking statements within the meaning of applicable securities laws and regulations including , but not limited to, statements regarding: the expected design, timing of initiation and receipt of topline results from the ALPHA - ORBIT trial; the goals and obje
Slide 3: Building a Leading Allergy and Immunology Company
3 ATOPIC DERMATITIS (AD) & BEYOND HEREDITARY ANGIOEDEMA (HAE) Building a Leading Allergy and Immunology Company • Half - life extended monoclonal antibody antagonist of OX40 • Clinically - validated mechanism • Potential best - in - class efficacy and safety • Half - life extended monoclonal antibod
Slide 4: Recent & Expected Milestones
RECENT & EXPECTED MILESTONES PHASE 3 PHASE 2 PHASE 1 PRECLINICAL DISCOVERY PROGRAM Q4 2024: Final results from Phase1b/2 ALPHA - STAR trial ⬥ Q1 2025: Phase 3 trial initiation ⬥ Mid - 2025: Initial results from ALPHA - SOLAR ⬥ Early 2027: Phase 3 ALPHA - ORBIT top - line results NAVENIBART (STAR - 0
Slide 5: Navenibart Phase 3 Program
Developing the Potential Market - Leading HAE Treatment: Navenibart Phase 3 Program • Single 6 - month pivotal Phase 3 trial and long - term extension designed with both Q3M and Q6M administration • Pioneering expected patient - centric dosing flexibility in HAE with potential market - leading first
Slide 6: Navenibart Designed for Best Patient Experience
Navenibart Designed for Best Patient Experience 6 Navenibart Vision SCIENCE THAT WORKS : • Monoclonal antibody inhibitor of plasma kallikrein • High affinity and potency with fast onset • YTE modification for extended half - life • Citrate - free, high - concentration formulation THERAPY THAT PATIEN
Slide 7: HAE: Significant Opportunity to Improve Lives
7 HAE: Significant Opportunity to Improve Lives PREVALENCE COMMERCIAL OPPORTUNITY 1 in 50,000 - 80,000 people worldwide (<8k US, <15k EU) 1,2,3,4 Market growth driven by: • Patients being diagnosed earlier • More patients taking preventative treatments • Geographic expansion for currently available
Slide 8: Phase 3 Trial Strategy
Phase 3 Trial Strategy • Our goal is to revolutionize the way that patients manage their HAE • Phase 3 designed to evaluate both Q3M and Q6M regimens with the goal of providing options for patients that, if approved, would ultimately create flexibility in how patients manage their disease • Planned
Slide 9: Single Global Phase 3 Pivotal Trial Design
9 1. Selected secondary endpoints shown. R = randomization 2. Banerji et al (2018), JAMA 3. TAKHZYRO US Prescribing Information (Feb 2023) 4.Astria QSP analysis A Single, Global Phase 3 Pivotal Trial Designed to Assess Efficacy and Safety for Both Q3M and Q6M Administration of Navenibart in HAE 6 -
Slide 10: Long-Term Extension Trial to Support Registration
Long - Term Extension Trial to Support Navenibart’s Registration and Profile in HAE 10 600mg Q3M 300mg Q3M 600 mg Q6M PHASE 3 LONG - TERM OPEN - LABEL EXTENSION TRIAL Part 1: 6 - month dose - controlled evaluation Part 2: Flexible dosing, open - label • ALPHA - ORBIT participants on drug may be elig
Slide 11: Path to ALPHA-ORBIT Success
Path to ALPHA - ORBIT Success 11 OUR COMMITMENT TO OPERATIONAL EXCELLENCE • Wide footprint, global trial • Robust physician outreach to date • Site recruiting activities are ongoing OUR HISTORY OF STRONG EXECUTION • Phase 1b/2 enrolled faster than anticipated • Expanded enrollment has allowed additi
Slide 12: ALPHA-STAR Informed Q3M and Q6M Dosing
SC = subcutaneous. Run - in period is at least 8 weeks (56 days) to measure baseline HAE attacks. Final data from target enrollment patients (n=16) 12 ALPHA - STAR Informed Q3M and Q6M Dosing SC Administration Trial Design Schematic 8 - week run - in 600 mg 600 mg COHORT 3 (n =6 ) Day 1 Day 28 8 - w
Slide 13: ALPHA-STAR Phase 1b/2 Results Established Proof-of-Concept
ALPHA - STAR Phase 1b/2 Results Established Proof - of - Concept and Path for Potential Phase 3 Success Navenibart efficacy endpoints are mean change from baseline. Final data from target enrollment patients (n=16). Results from lanadelumab , berotralstat , garadacimab , and donidalorsen are from se
Slide 14: Months of HAE Attack Prevention with 1 or 2 Doses
14 Navenibart Demonstrated 6 Months of HAE Attack Prevention with 1 or 2 Doses Final data from target enrollment patients (n=16). Showing %difference between the means in each group (3 months and 6 months) vs the mean run - in (baseline). C o h o r t 1 ( n = 4 ) C o h o r t 2 ( n = 6 ) C o h o r t 3
Slide 15: Navenibart Well-Tolerated with Favorable Safety Profile
Navenibart Was Well - Tolerated and Demonstrated a Favorable Safety Profile 15 1. One participant experienced mild dizziness occurring 6 days after the first dose in Cohort 2 and lasting < 1 day; One participant experienced 2 injection site reactions: injection site erythema and injection site pruri
Slide 16: PK and PD Consistent with Rapid and Durable Clinical Benefit
Results Show that Navenibart PK and PD Are Consistent with Rapid and Durable Clinical Benefit 16 Final data from target enrollment patients (n=16). 1 . Wang et al (2020), Lanadelumab FDA Multidisciplinary Review (2017): maximum 53.7% inhibition of formation rate of cHMWK with lanadelumab (exposure -
Slide 17: Mechanistic QSP Model Informed Phase 3 Dose Selection
17 Species: XII = factor XII, XIIa = activated factor XII, C1 - Inh = C1 - inhibitor, HMWK = high molecular weight kininogen, cHMWK = cleaved HMWK, Kallikrein = plasma kallikrein, PK = pharmacokinetics, PD = pharmacodynamics 1. Sexton D et al (2024) J Pharmacokinet Pharmacodyn Mechanistic QSP Model
Slide 18: Potential to be the Market-Leading HAE Preventative Therapy
Navenibart Has the Potential to be the Market - Leading HAE Preventative Therapy 1. Mean “ 5 and 95 percentiles from 100 subsets of virtual population with ~ 100 subjects in each subset. Ranges of mean reductions in 6 - month time - normalized monthly HAE attack rates through 24 months are shown. Na
Slide 19: Dosing Flexibility Has Potential to Transform HAE Treatment
Navenibart Dosing Flexibility Has the Potential to Transform the Treatment of HAE 19 1. Roche. YTD September 2024 sales (2024). 2. Takeda Pharmaceutical Co. Takeda Quarterly Financial Report For the Quarter Ended March 31, 2024. (2024). 3. Takeda Pharmaceutical Co. Takeda Quarterly Financial Report
Slide 20: Advancing Navenibart to Become the Potential Market-Leading Treatment
Advancing Navenibart to Become the Potential Market - Leading Treatment for HAE 20 Compelling Navenibart Clinical Profile that Supports Potential Q3M and Q6M Administration Growing HAE Market Expected to be $5.4B by 2030 Pioneering Potential Patient - Centric Dosing Flexibility Building Expected Pat
Slide 21: Q3M and Q6M Options Address Broader Population
Providing Patients Both Q3M and Q6M Options Would Allow Individual Choice and Address the Needs of a Broader Population 21 TRINITY Primary Market Research, July – August 2024; Quantitative Research with N=50 U.S. HAE Treaters; Shares reported with res pect to currently available treatments *Blinded
Slide 22: Navenibart Expected to Draw Switches from Other Therapies
Navenibart Expected to Draw Switches from Other Current Therapies 22 TRINITY Primary Market Research, July – August 2024; Quantitative Research with N=50 U.S. HAE Treaters; Shares reported with res pect to currently available treatments *Blinded profile shared of a monoclonal antibody inhibitor of p
Slide 23: Navenibart Expected to Draw Newly Initiating Patients
Navenibart Expected to Draw Patients From Newly Initiating Preventative Therapies 23 TRINITY Primary Market Research, July – August 2024; Quantitative Research with N=50 U.S. HAE Treaters; Shares reported with res pect to currently available treatments *Blinded profile shared of a monoclonal antibod
Slide 24: Patient quote on dosing freedom
Taking a medication 2 or 4 times a year would mean freedom for me. That is the closest thing to a normal life that I could imagine. I could travel. I could make plans without checking the day of the week.” COLI ”
Slide 25: OX40 Has Broad Opportunities in Allergy and Immunology
25 OX40 Has Broad Opportunities in Allergy and Immunology Atopic Dermatitis Asthma Celiac Scleroderma Hidradenitis Suppurativa Alopecia Areata New indications Combinations Bispecific/ multispecific antibodies
Slide 26: Atopic Dermatitis: Opportunity for Broad Impact
Atopic Dermatitis: Opportunity for Broad Impact on Patients’ Lives PREVALENCE COMMERCIAL OPPORTUNITY 16 million people in the U.S. have AD 1 About half of those people are reported to be moderate - to - severe 1 $5Bn $24Bn Treatment Topicals and immunosuppressants Advanced treatment* 2023 Moderate -
Slide 27: Precedence for Market Growth in Targeted Dermatology Therapies
US Prevalence Psoriasis: 2 - 3% 3 Atopic Dermatitis: 5% 4 Proven Precedence for Market Growth and Evolution for Targeted Dermatology Therapies * Includes Cibinqo and Rinvoq . 1. Evaluate Pharma Consensus Sales by Indication in the US 2. Decision Resources Group: Atopic Dermatitis Disease Landscape &
Slide 28: Targeting OX40 Has Potential for Disease Modification
Targeting OX40 Has Potential for Disease Modification 28 • AD is driven by a diversity of T cells, including Th1, Th2 and Th17/22 • Current biologics target only the Th2 pathway • Targeting OX40 impacts Th cells broadly and may result in higher rates of clinical response Current biologics
Slide 29: STAR-0310 Potential for Differentiation from Late-Stage OX40 Programs
STAR - 0310 Shows Potential for Differentiation from Late - Stage OX40/OX40L Programs 29 Rocatinlimab 2,3,6 Amlitelimab 1,2,5 STAR - 0310 APCs=antigen presenting cells. These include epithelial, endothelial, smooth muscle, mast and B cells. AEs= adverse events 1. Weidinger et al, 2023; Br J Dermatol
Slide 30: STAR-0310: Engineered to Differentiate
STAR - 0310: Engineered to Differentiate on Efficacy, Safety, and Treatment Burden 30 Extended Half - Life with YTE technology Potential Best - in - Class Safety Profile Designed for low ADCC and to be T cell preserving High Affinity, Next Generation Anti - OX40 antibody Selective Potency for Activa
Slide 31: STAR-0310 Has High Potency for OX40
STAR - 0310 Has High Potency for OX40 31 STAR - 0310 and Rocatinlimab Have Similar Potency on Effector T (Th) Cells Th1 cytokine 0 . 1 1 1 0 1 0 0 1 0 0 0 0 5×10 4 1×10 5 1.5×10 5 2×10 5 IFNγ Concentration (nM) C y t o k i n e r e l e a s e ( p g / m L ) OKT3+OX40L OKT3 0 . 1 1 1 0 1 0 0 1 0 0 0 0 5
Slide 32: STAR-0310 Is Engineered for Low ADCC
STAR - 0310 Is Engineered for Low ADCC 32 STAR - 0310 Has Lower ADCC than Rocatinlimab 0.0001 0.01 1 100 0 50 100 Concentration (nM) A D C C ( % ) o f a c t i v a t e d T c e l l s STAR-0310 AMG451 ADCC on Activated T Cells 0.0001 0.01 1 100 0 50 100 Concentration (nM) A D C C ( % ) o f T r e g c e
Slide 33: STAR-0310 Potential for Best-in-Class Efficacy
STAR - 0310 Has Potential for Best - in - Class Efficacy 33 1. Figures represent a cross - experiment comparison 2. Biris , et al. “Development and characterization of STAR - 0310: a novel OX40 antagonistic monoclonal antibody. EAACI May 2024 . STAR - 0310 Has a Potentially Wider Therapeutic Window
Slide 34: Potential to be Least Frequently Administered OX40
STAR - 0310 Has Potential to be the Least Frequently Administered OX40 34 NHP = Nonhuman primate Single dose in vivo pharmacokinetic data from cynomolgus monkeys dosed with STAR - 0310 via subcutaneous (SC, N= 3) route at 20 mg /kg. Biris, et al. “Development and characterization of STAR - 0310: a n
Slide 35: STAR-0310: Potential First-Choice for Moderate-to-Severe AD
35 STAR - 0310: Potential First - Choice for Moderate - to - Severe AD Phase 1a Initiation Anticipated in Q1 2025 Better Safety and Tolerability Best - in - Class Efficacy Least Frequently Administered OX40
Slide 36: Recent and Expected Milestones
ATOPIC DERMATITIS HEREDITARY ANGIOEDEMA Recent and Expected Milestones 36 Q3 & Q4 2024: Orphan Drug and Orphan Medicinal Product Designations Q1 2025: Initiate Phase 3 trial Mid - 2025: Long - term treatment results from ALPHA - SOLAR YE 2024: IND submission Q1 2025: Initiate Phase 1a healthy subjec
Slide 37: Strong Financial Foundation
Strong Financial Foundation 37 1. The Company expects that its cash, cash equivalents and short - term investments as of September 30, 2024 will be sufficient to fu nd its operations into mid - 2027, including all navenibart program activities through the completion of a planned Phase 3 pivotal tria
Slide 38: Slide 38
Astria Therapeutics — Investor Presentation (January 2025) on 6ix